Candida infection in very low birth-weight infants: Outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome®)

Infection

Volumn 26, Issue 1, 1998, Pages 11-15

  Weitkamp, J H ^a   Poets, C F ^b   Sievers, R ^c   Musswessels, E ^e   Groneck, P ^d   Thomas, P ^f   Bartmann, P ^a  

^a UNIVERSITY OF BONN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c KINDERKRANKENHAUS AUF DER BULT   (Germany)

^d Stadtische Kliniken K   (Germany)

^e Märkische Kinderklinik Hamm   (Germany)

^f HELIOS KLINIKUM KREFELD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CREATININE; DRUG CARRIER; LIPOSOME; POTASSIUM;

ARTICLE; CANDIDIASIS; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIET SUPPLEMENTATION; DRUG CHOICE; DRUG MECHANISM; DRUG SAFETY; GESTATIONAL AGE; HUMAN; HYPOKALEMIA; LOW BIRTH WEIGHT; MICROENCAPSULATION; MYCOSIS; NEPHROTOXICITY; NEWBORN; TREATMENT OUTCOME;

EID: 0031975606     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02768745     Document Type: Article

References (34)

1. Baley, J. E., Kliegman, R. M., Fanaroff, A. A.: Disseminated fungal infections in very low birth-weight infants: clinical manifestations and epidemiology. Pediatrics 73 (1984) 144-152.
2. Baley, J. E., Silverman, A.: Systemic candidiasis: cutaneous manifestations in low birth-weight infants. Pediatrics 82 (1988) 211-215.
3. Faix, R. G., Kovarik, S. M., Shaw, T. R., Johnson, R. V.: Mucocutaneous and invasive candidiasis among very low birth-weight (< 1,500 grams) infants in intensive care nurseries: a prospective study. Pediatrics 83 (1989) 101-107.
4. Johnson, D. E., Thompson, T. R., Grenn, T. P., Ferrieri, P.: Systemic candidiasis in very low birth-weight infants (< 1,500 grams). Pediatrics 73 (1984) 138-143.
5. Wainer, S., Cooper, P. A., Funk, E., Bental, R. Y., Sandelr, D. A., Patel, J.: Prophylactic miconazole oral gel for the prevention of neonatal fungal rectal colonization and systemic infection. Pediatr. Infect. Dis. J. 11 (1992) 713-716.
6. Weese-Mayer, D. E., Fondriest, D. W., Brouillette, R. T., Shulman, S. T.: Risk factors associated with candidemia in the neonatal intensive care unit: a case-control study. Pediatr. Infect. Dis. J. 6 (1987) 190-196.
7. Ng, P. C.: Systemic fungal infections in neonates. Arch. Dis. Child. 71 (1994) F130-F135.
8. Baley, J. E., Kliegman, R. M., Boxerbaum, B., Fanaroff, A. A.: Fungal colonization in the very low birth weight infant. Pediatrics 78 (1986) 225-232.
9. Warnock, D. W.: Amphotericin B: an introduction. J. Antimicrob. Chemother. 28 (1991) 27-38.
10. Burgess, J. L., Birchall, R.: Nephrotoxicity of amphotericin B, with emphasis on changes in tubular function. Am. J. Med. 53 (1972) 77-84.
11. Faix, R. G.: Systemic Candida infections in infants in intensive care nurseries: high incidence of central nervous system involvement. J. Pediatr. 105 (1984) 616-622.
12. Baley, J. E., Meyers, C., Kliegman, R. M., Jacobs, M. R., Blumer, J. L.: Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J. Pediatr. 116 (1990) 791-797.
13. Bornkessel, B.: Amphotericin B. Arzneimitteltherapie extra 20 (1995) 1-8.
14. Hay, R. J.: Liposomal amphotericin B, AmBisome®. J. Infection 28 (1994) 35-43.
15. Ringdén, O., Tollemar, J., Tydén, G.: Liposomal amphotericin B. Lancet 339 (1992) 374.
16. Tollemar, J., Andersson, S., Ringden, O., Tyden, G.: A retrospective clinical comparison between antifungal treatment with liposomal amphotericin B (AmBisome®) and conventional amphotericin B in transplant recipients. Mycoses 35 (1992) 215-220.
17. Proffitt, R. T., Satorius, A., Chiang, S.-M., Sullivan, L., Adler-Moore, J. P.: Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome®) in rodents. J. Antimicrob. Chemother. 28 (1991) 49-61.
18. Ringdén, O., Andstrom, E., Remberger, M., Svahn, B. M., Tollemar, J.: Safety of liposomal amphotericin B (AmBisome®) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transplant. 14 (1994) 10-14.
19. Zoubek, A., Emminger, W., Emminger-Schmidmeier, W., Peters, C., Pracher, E., Grois, N., Gadner, H.: Conventional vs. liposomal amphotericin B in immunosuppressed children. Pediatr. Hematol. Oncol. 9 (1992) 187-190.
20. Ringdén, O., Tollemar, J.: Liposomal amphotericin B (AmBisome®) treatment of invasive fungal infections in immunocompromised children. Mycosis 36 (1993) 187-192.
21. van Etten, E. W. M., van den Heuvel-de Groot, C., Bakker-Woudenberg, I. A. J. M.: Efficacies of amphotericin B-desoxycholate (Fungizone). liposomal amphotericin B (AmBisome®), and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice. J. Antimicrob. Chemother. 32 (1993) 723-739.
22. Arning, M., Kliche, K. O., Heer-Sonderhoff, A. H., Wehmeier, A.: Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 38 (1995) 459-465.
23. Meunier, F., Prentice, H. G., Ringden, O.: Liposomal amphotericin B (AmBisome®): safety data from a phase 2/3 clinical trial. J. Antimicrob. Chemother. 28 (1991) 83-91.
24. Laing, R. B. S., Milne, L. J. R., Leen, C. L. S., Malcolm, G. P., Steers, A. J. W.: Anaphylactic reactions to liposomal amphotericin. Lancet 344 (1994) 682.
25. Schneemann, H.: Liposomales Amphotericin B. Krankenhauspharmazie 13 (1992) 161-171.
26. Lackner, H., Schwinger, W., Urban, C., Müller, W., Ritschl, E., Reiterer, F., Kuttnig-Haim, M., Urlesberger, B., Hauer, C.: Liposomal amphotericin-B (AmBisome®) for treatment of disseminated fungal infections in two infants of very low birth weight. Pediatrics 89 (1992) 1259-1261.
27. DaSilva, L. P., Amaral, J. M. V., Ferreira, N. C.: Which is the most appropriate dosage of liposomal amphotericin-B (AmBisome®) for the treatment of fungal infections in infants of very low birth weight? Pediatrics 91 (1993) 1217-1218.
28. Sievers, R., Neubauer, A.-P., Natzschka, J.: Therapie mit liposomalem Amphotericin B bei neonataler Pilzsepsis mit enzephalitischer und osteoarthritischer Beteiligung. Monatsschr. Kinderheilkd. 142 (1994) 266-268.
29. Kläber, H.-G., Erler, Th., Hummel, H.: Behandlung der neonatalen Pilzsepsis. Liposomales Amphotericin B als Mittel der 1. Wahl? In: Sitzmann, F. C. (ed.): Infektionen und Pilze im Kindesalter. Hans Marseille Verlag, München 1995, pp. 217-221.
30. Schneider, H. C., Frauendienst-Egger, G., Trefz, F. K.: Die Behandlung systemischer Candidainfektionen bei sehr kleinen Frühgeborenen. Einsatz von liposomalem Amphotericin B. Monatsschr. Kinderheilkd. 4 (1996) 458 P1.
31. AmBisome-Produktmonographie, Vestar Inc. (1994).
32. Ringdén, O., Andström, E., Remberger, M., Svahn, B.-M., Tollemar, J.: Allergic reactions and other rare side-effects of liposomal amphotericin. Lancet 344 (1994) 1156-1157.
33. Aperia, A., Broberger, O., Elinder, G., Herin, P., Zetterström, R.: Postnatal development of renal function in pre-term and full-term infants. Acta Paediatr. Scand. 70 (1981) 183-187.
34. Bueva, A., Guignard, J.-P.: Renal function in preterm neonates. Pediatr. Res. 36 (1994) 572-577.